These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19759414)

  • 1. LOH at 1p31 (ARHI) and proliferation in lymph node-negative breast cancer.
    Janssen EA; Øvestad IT; Skaland I; Søiland H; Gudlaugsson E; Kjellevold KH; Nysted A; Søreide JA; Baak JP
    Cell Oncol; 2009; 31(5):335-43. PubMed ID: 19759414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer.
    Klintman M; Strand C; Ahlin C; Beglerbegovic S; Fjällskog ML; Grabau D; Gudlaugsson E; Janssen EA; Lövgren K; Skaland I; Bendahl PO; Malmström P; Baak JP; Fernö M
    PLoS One; 2013; 8(12):e81902. PubMed ID: 24324728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T₁₋₂N₀M₀ breast cancer.
    Gudlaugsson E; Klos J; Skaland I; Janssen EA; Smaaland R; Feng W; Shao Z; Malpica A; Baak JP
    Pol J Pathol; 2013 Apr; 64(1):1-8. PubMed ID: 23625593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D2-40/p63 defined lymph vessel invasion has additional prognostic value in highly proliferating operable node negative breast cancer patients.
    Gudlaugsson E; Skaland I; Undersrud E; Janssen EA; Søiland H; Baak JP
    Mod Pathol; 2011 Apr; 24(4):502-11. PubMed ID: 21317878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphohistone H3 expression has much stronger prognostic value than classical prognosticators in invasive lymph node-negative breast cancer patients less than 55 years of age.
    Skaland I; Janssen EA; Gudlaugsson E; Klos J; Kjellevold KH; Søiland H; Baak JP
    Mod Pathol; 2007 Dec; 20(12):1307-15. PubMed ID: 17917671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic value of MARCKS-like 1 in lymph node-negative breast cancer.
    Jonsdottir K; Zhang H; Jhagroe D; Skaland I; Slewa A; Björkblom B; Coffey ET; Gudlaugsson E; Smaaland R; Janssen EA; Baak JP
    Breast Cancer Res Treat; 2012 Sep; 135(2):381-90. PubMed ID: 22772381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of the proliferation marker phosphohistone H3 (PPH3) in luminal, basal-like and triple negative phenotype invasive lymph node-negative breast cancer.
    Skaland I; Janssen EA; Gudlaugsson E; Hui Ru Guo L; Baak JP
    Cell Oncol; 2009; 31(4):261-71. PubMed ID: 19633363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing the prognostic value of PTEN and Akt expression with the Mitotic Activity Index in adjuvant chemotherapy-treated node-negative breast cancer patients aged <55 years.
    Janssen EA; Søiland H; Skaland I; Gudlaugson E; Kjellevold KH; Nysted A; Søreide JA; Baak JP
    Cell Oncol; 2007; 29(1):25-35. PubMed ID: 17429139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer.
    Jonsdottir K; Assmus J; Slewa A; Gudlaugsson E; Skaland I; Baak JP; Janssen EA
    PLoS One; 2014; 9(3):e90642. PubMed ID: 24599057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor.
    Janssen EA; Baak JP; Guervós MA; van Diest PJ; Jiwa M; Hermsen MA
    J Pathol; 2003 Dec; 201(4):555-61. PubMed ID: 14648658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Mitotic Activity Index in combination with Her2neu: a strong prognosticator in breast cancer.
    Jobsen JJ; Struikmans H; van der Palen J; Siemerink E
    Breast Cancer Res Treat; 2020 May; 181(1):13-21. PubMed ID: 32232697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers.
    Peng H; Xu F; Pershad R; Hunt KK; Frazier ML; Berchuck A; Gray JW; Hogg D; Bast RC; Yu Y
    Int J Cancer; 2000 Jun; 86(5):690-4. PubMed ID: 10797292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent.
    Baak JP; van Diest PJ; Voorhorst FJ; van der Wall E; Beex LV; Vermorken JB; Janssen EA; Gudlaugsson E;
    Eur J Cancer; 2007 Feb; 43(3):527-35. PubMed ID: 17110097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers.
    Baak JP; Gudlaugsson E; Skaland I; Guo LH; Klos J; Lende TH; Søiland H; Janssen EA; Zur Hausen A
    Breast Cancer Res Treat; 2009 May; 115(2):241-54. PubMed ID: 18665447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer.
    Williams DJ; Cohen C; Darrow M; Page AJ; Chastain B; Adams AL
    Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):431-6. PubMed ID: 21297447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validating the prognostic value of proliferation measured by Phosphohistone H3 (PPH3) in invasive lymph node-negative breast cancer patients less than 71 years of age.
    Skaland I; Janssen EA; Gudlaugsson E; Klos J; Kjellevold KH; Søiland H; Baak JP
    Breast Cancer Res Treat; 2009 Mar; 114(1):39-45. PubMed ID: 18373192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic significance of loss of heterozygosity in breast cancer].
    Iwase H; Iwata H; Toyama T; Hara Y; Omoto Y; Kobayashi S
    Gan To Kagaku Ryoho; 1998 Apr; 25 Suppl 3():426-30. PubMed ID: 9589047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivariate prognostic evaluation of the mitotic activity index and fibrotic focus in node-negative invasive breast cancers.
    Baak JP; Colpaert CG; van Diest PJ; Janssen E; van Diermen B; Albernaz E; Vermeulen PB; Van Marck EA
    Eur J Cancer; 2005 Sep; 41(14):2093-101. PubMed ID: 16153819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphohistone H3 outperforms Ki67 as a marker of outcome for breast cancer patients.
    Gerring Z; Pearson JF; Morrin HR; Robinson BA; Harris GC; Walker LC
    Histopathology; 2015 Oct; 67(4):538-47. PubMed ID: 25728258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years.
    Baak JP; van Diest PJ; Voorhorst FJ; van der Wall E; Beex LV; Vermorken JB; Janssen EA
    J Clin Oncol; 2005 Sep; 23(25):5993-6001. PubMed ID: 16135467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.